Get 2 months free with an annual subscription at
was
€65.88
now
€54.
Weight-loss drugs and Mars bars: Novo Nordisk’s comeback bid
The maker of Wegovy and Ozempic wants to learn lessons from consumer groups to crack the US market
147 words~1 min read
Related reading
How Novo Nordisk lost its lead in the weight loss race
Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors
Battle for weight-loss supremacy shifts from jabs to pills
Novo Nordisk’s Wegovy tablet offers Danish drugmaker window to win back market share from Eli Lilly
Pharma just ‘scratching the surface’ of weight-loss drug market
Novo Nordisk chief estimates industry reaching only 15% of potential customers at most
Novo Nordisk faces more gloom from price cuts in crowded anti-obesity drugs…
Danish group’s challenges mount despite winning reprieve after Hims & Hers withdraws plan to sell copycat Wegovy pill
Triple dose of Novo Nordisk drug delivers 19% weight loss in trials
Danish pharma group seeks to broaden options and stay competitive with Eli Lilly
Novo Nordisk shares plunge after profit warning over US weight-loss copycats
Share slide wipes more than €60bn off value of Danish maker of Ozempic and Wegovy